Zanzalintinib (XL092): a next-generation tyrosine kinase inhibitor—comprehensive review of early safety & efficacy data-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Zanzalintinib (XL092): a next-generation tyrosine kinase inhibitor—comprehensive review of early safety & efficacy data

Published:2024-08-07 Issue: Volume: Page:1-9
ISSN:1354-3784
Container-title:Expert Opinion on Investigational Drugs
language:en
Short-container-title:Expert Opinion on Investigational Drugs

Author:

Yu James¹,Park Robin¹,Tojjari Alireza²,Sadeghipour Arezoo³,Saeed Ali⁴,Saeed Anwaar²

Affiliation:

1. Division of Hematology and Medical Oncology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, USA

2. Department of Medicine, Division of Hematology and Oncology, UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, PA, USA

3. Department of Biochemistry, Faculty of Biological Sciences, Tarbiat Modarres University, Tehran, Iran

4. Department of Medicine, Ochsner Lafayette General Medical Center, Lafayette, LA, USA

Publisher

Informa UK Limited

Link

https://www.tandfonline.com/doi/pdf/10.1080/13543784.2024.2388571

Reference47 articles.

1. Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): long-term follow-up results from an open-label, randomised, phase 3 trial

2. Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma

3. Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma

4. Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma

5. Signal Transduction by Vascular Endothelial Growth Factor Receptors

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP